利特昔替尼可以和其他药物一起服用吗?

In terms of drug interactions, ritexitinib may interact with other drugs when used at the same time, so patients should inform their doctors of any other drugs they take during treatment with ritixitinib.

In order to ensure the safety and therapeutic effect of the drug, patients should follow the doctor's advice while using ritexitinib and do not use it with other drugs at the same time. If necessary, consult your doctor and inform him of any medications you are taking.

Drugs that can be combined with ritexitinib

1. Strong CYP3A inhibitor: itraconazole, the recommended dose is 200 mg once a day × 5 days, and the dose of ritexitinib is 30 mg.

2. Strong CYP enzyme inducer: rifampicin, the recommended dose is 600 mg once a day × 8 days, and the dose of ritexitinib is 30 mg.

3. Oral contraceptives: ethinyl estradiol and levonorgestrel. When used in combination, the dose of ritexitinib is 50 mg once a day × 11 days.

4. Sensitive CYP3A substrate: midazolam. When used in combination with ritexitinib, the dose is 200 mg once a day × 11 days.

5. Sensitive CYP1A2 substrate: caffeine. When used in combination, the dose of ritexitinib is 200 mg once a day × 9 days.

6. Sensitive CYP2B6 substrate: efavirenz, the dose of ritexitinib when used in combination is 200 mg once a day × 11 days.

7. Sensitive CYP2C substrate: tolbutamide, the dose of ritexitinib when used in combination is 200 mg once a day × 10 days.

Contraindications for sharing ritexitinib with other drugs

1. Ritexitinib is a CYP3A inhibitor. Coadministration can increase the AUC and Cmax of CYP3A substrates, which may increase the risk of adverse reactions with these substrates.

2. Ritexitinib is a CYP1A2 inhibitor. Concomitant use of ritexitinib may increase the AUC and Cmax of CYP1A2 substrates, which may increase the risk of adverse reactions with these substrates.

3. Coadministration with strong CYP3A inducers is not recommended. Concomitant use of strong CYP3A inducers (such as rifampicin) may reduce the AUC and Cmax of ritexitinib, which may lead to loss or reduction of clinical response.

Other precautions for ritixitinib

1. Inform patients that they may develop infections while taking ritixitinib, which may be serious in some cases. Instruct patients to tell their doctor if they develop any signs or symptoms of infection.

2. Inform patients that ritexitinib may increase their risk of certain cancers, including skin cancer. Regular skin examinations are recommended while using ritexitinib.

3. Inform patients that PE and retinal artery occlusion events were reported in clinical trials of ritexitinib. Tell your doctor if you develop any signs or symptoms of blood clots.

4. If the patient develops any signs and symptoms of severe allergic reaction, it is recommended that the patient stop using ritexitinib and seek medical attention immediately.

5. It is recommended that patients not receive live vaccines during and shortly before ritixitinib treatment. Instruct patients to inform their healthcare provider before possible vaccination that they are taking it.

6. It is recommended that pregnant women and women of reproductive potential please inform their doctor if they become pregnant or plan to become pregnant during treatment with ritexitinib.

Note: The above information comes from the U.S. FDA drug instructions and network integration. Please follow your doctor's advice when taking medication and do not use it blindly.

Recommended hot articles: